|
|
|||||
Andy Oram
Andy Oram is an editor at O'Reilly Media. An employee of the company
since 1992, Andy currently specializes in open source technologies and
software engineering. His work for O'Reilly includes the first books
ever released by a U.S. publisher on Linux, the 2001 title
Peer-to-Peer, and the 2007 best-seller Beautiful Code.
Health Information Technology: putting the patient back into health care
In health information technology, we have a rare chance to ensure that the most affected members of the public actually have their own direct representative. A letter in support of Regina Holliday.
How to start a successful business in health care at Health 2.0 conference
Great piles of cash are descending on entrepreneurs who develop health care apps, but that doesn't make it any easier to create a useful one that your audience will adopt. About the Spring Fling conference, enterpreneurship, and open data.
Lucene conference touches many areas of growth in search
With a modern search engine and smart planning, web sites can provide visitors with a better search experience than Google. Why turn-out for the new "big data" track was lower than I expected, and other news from this week's conference about using Lucene big and small.
The state of health IT according to the American Hospital Association
The letter conveys a rather sorrowful message about the state of health IT in the United States. One request--to put brakes on the requirement for hospitals to let patients see their own information electronically--has received particularly strong coverage and vigorous responses.
Recombinant Research: Breaking open rewards and incentivesCan open data dominate biological science as open source has in software?
To move from a hothouse environment of experimentation to the mainstream of one of the world's most lucrative and tradition-bound industries, Sage Bionetworks must aim for its nucleus: rewards and incentives. Comparisons to open source software and a summary of tasks for Sage Congress.
Recombinant Research: Sage Congress plans for patient engagement
The Vioxx problem is just one instance of the wider malaise afflicting the drug industry. Managers from major pharma companies expressed confidence that they could expand public or "pre-competitive" research in the direction Sage Congress proposed. The sector left to engage is the one that's central to all this work--the public.
|
|||||
© 2012, O'Reilly Media, Inc. (707) 827-7019(800) 889-8969 All trademarks and registered trademarks appearing on oreilly.com are the property of their respective owners. |
|||||
Check out Andy Oram's 
Follow Andy Oram on 
Subscribe to 
Sign up for the